GF Fund Management’s Aquestive Therapeutics AQST Stock Holding History

GF Fund Management’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$13K	Buy	2,813 +230	+9%	+$1.02K	﹤0.01%	526
2026 Q2	$10.7K	Sell	2,583 -144	-5%	-$606	﹤0.01%	531
2026 Q1	$11.3K	Buy	2,727 +330	+14%	+$1.34K	﹤0.01%	551
2025 Q4	$15.5K	Sell	2,397 -206	-8%	-$1.28K	﹤0.01%	534
2025 Q3	$14.6K	Buy	2,603 +341	+15%	+$1.47K	﹤0.01%	523
2025 Q2	$7.49K	Hold	2,262	–	–	﹤0.01%	598
2025 Q1	$6.56K	Buy	2,262 +348	+18%	+$1.05K	﹤0.01%	606
2024 Q4	$6.81K	Buy	+1,914	New	+$8.83K	﹤0.01%	591

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $45.4M AUM 17.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $52.3B AUM 19.7% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

GF Fund Management's AQST Position: Q3 2026 in Review

GF Fund Management increased its Aquestive Therapeutics (AQST) stake by 8.9% in Q3 2026, buying an estimated $1.02K and bringing the position to 2,813 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #526.

GF Fund Management first reported a position in AQST in Q4 2024 and has held it in 8 quarters since. The position peaked at $15.5K in Q4 2025. 110 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

GF Fund Management held 2,813 shares of Aquestive Therapeutics worth $13K as of Q3 2026.
GF Fund Management bought 230 Aquestive Therapeutics shares in Q3 2026, an estimated $1.02K.
Aquestive Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #526 holding.
GF Fund Management first reported a position in Aquestive Therapeutics in Q4 2024 and has held it in 8 quarters since.
GF Fund Management's Aquestive Therapeutics position peaked at $15.5K in Q4 2025.
110 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.